Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 7/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802031 | 1.00 | KDM5A (0.34) | KDM5AL3MBTL3L3MBTL1PNPAURKA | |
| SCHEMBL21281473 | 0.83 | SRC (0.46) | L3MBTL1EGFRSRC | |
| SCHEMBL22822745 | 0.83 | SRC (0.46) | L3MBTL1EGFRSRC | |
| SCHEMBL22801997 | 0.79 | HTR6 (0.36) | AURKASRC | |
| SCHEMBL22801941 | 0.77 | HCAR1 (0.45) | L3MBTL1 | |
| SCHEMBL22801981 | 0.76 | KDM1A (0.36) | KDM5A | |
| SCHEMBL22801983 | 0.76 | KDM1A (0.36) | KDM5A | |
| SCHEMBL31324653 | 0.74 | AURKA (0.38) | AURKASRC | |
| SCHEMBL22822703 | 0.74 | AURKA (0.36) | AURKASRC | |
| SCHEMBL20135661 | 0.74 | KDM5A (0.35) | KDM5AAURKAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | KDM5A 2233/4885L3MBTL3 4757/4885L3MBTL1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.